3-{[(Imino{[(methylamino)carbonyl]amino}methyl)amino]methyl}-1,1'-biphenyl

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-{[(Imino{[(methylamino)carbonyl]amino}methyl)amino]methyl}-1,1'-biphenyl
• 英文别名: 1-methyl-3-[N'-[(3-phenylphenyl)methyl]carbamimidoyl]urea
• 化学式: C₁₆H₁₈N₄O
• 分子量: 282.345
• InChiKey: HUWNGIKQIOUUCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  79.5
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis
  申请人：——

  公开号：US20040044037A1

  公开（公告）日：2004-03-04

  Novel amidino-urea 5-HT 7 receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treating sleep disorders, pain, depression, and schizophrenia employing the receptor ligands are disclosed. The receptor ligands have formula (1): wherein the formula variables are as defined herein, and pharmaceutically acceptable salts, solvates, active metabolites, or prodrugs thereof.

  揭示了一种新型的胍基脲5-HT7受体配体，以及制备这种配体的方法、在配体制备中有用的中间化合物、包括该受体配体的药物组合物，以及利用该受体配体治疗睡眠障碍、疼痛、抑郁症和精神分裂症的方法。该受体配体具有化学式（1）：其中化学式变量如本文所定义，以及其药用盐、溶剂合物、活性代谢产物或前药。
• AMIDINO-UREA SEROTONIN RECEPTOR LIGANDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND METHODS FOR THEIR SNYTHESIS
  申请人：Warner-Lambert Company LLC

  公开号：EP1332127A2

  公开（公告）日：2003-08-06
• [EN] AMIDINO-UREA SEROTONIN RECEPTOR LIGANDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND METHODS FOR THEIR SNYTHESIS<br/>[FR] LIGANDS DU RECEPTEUR DE LA SEROTONINE AMIDINO-UREE ET COMPOSITIONS, LEURS APPLICATIONS PHARMACEUTIQUES ET LEURS PROCEDES DE SYNTHESE
  申请人：WARNER LAMBERT CO

  公开号：WO2002036554A2

  公开（公告）日：2002-05-10

  Novel amidino-urea 5-HT7 receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treating sleep disorders, pain, depression, and schizophrenia employing the receptor ligands are disclosed. The receptor ligands have formula (1): wherein the formula variables are as defined herein, and pharmaceutically acceptable salts, solvates, active metabolites, or prodrugs thereof.